文献速递神经技术与安全MR

钆吡多醇的疗效与安全性综合概述:一种用于中枢神经系统及体部磁共振成像的新型对比剂

A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body.
PubMed 文献 · Invest Radiol · 2023-10-09

本文综述了新型大环类钆基对比剂钆吡多醇的药代动力学、疗效与安全性。美国食品药品监督管理局已批准其0.05 mmol/kg剂量用于中枢神经系统及体部增强磁共振成像。研究显示其在该剂量下对病灶显示不劣于钆布醇0.1 mmol/kg,且安全性良好。

要点

  • 钆吡多醇0.05 mmol/kg在病灶显示三项参数上不劣于钆布醇0.1 mmol/kg。
  • 在中枢神经系统增强磁共振成像中,钆吡多醇0.1 mmol/kg的对比噪声比优于钆贝葡胺0.1 mmol/kg。
  • 2至17岁儿童患者的药代动力学参数与成人相当,无需按年龄调整剂量。

核心结论

  • 钆吡多醇0.05 mmol/kg在成人及2岁及以上儿童的中枢神经系统和体部磁共振成像中具有临床实用性和安全性。

研究设计与样本

  • 综述,描述钆吡多醇的药代动力学、疗效和安全性,并汇总了包含1047名参与者的安全性分析。

诊断标准与关键数值

  • 钆吡多醇0.05 mmol/kg与钆布醇0.1 mmol/kg在病灶边缘勾勒、内部形态和对比增强三项病灶显示参数上不劣。
  • 在中枢神经系统增强磁共振成像中,钆吡多醇0.1 mmol/kg的对比噪声比优于钆贝葡胺0.1 mmol/kg,而钆吡多醇0.05 mmol/kg的对比噪声比与钆贝葡胺0.1 mmol/kg相当。
  • 美国食品药品监督管理局批准的钆吡多醇剂量为0.05 mmol/kg。

临床应用与阅片要点

  • 钆吡多醇是一种高弛豫率大环类钆基对比剂,主要经肾脏排泄。
  • 在2至17岁儿童患者中,群体药代动力学模型评估的参数与成人相当,提示无需基于年龄调整剂量。
  • 汇总安全性分析显示钆吡多醇安全性良好,不良反应的发生率和性质与其他钆基对比剂相当。
  • 在儿童、老年及肾功能损害患者中未发现显著安全性问题。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

This review describes the pharmacokinetics, efficacy, and safety of gadopiclenol, a new macrocyclic gadolinium-based contrast agent (GBCA) recently approved by the Food and Drug Administration at the dose of 0.05 mmol/kg. Gadopiclenol is a high relaxivity contrast agent that shares similar pharmacokinetic characteristics with other macrocyclic GBCAs, including a predominant renal excretion. In pediatric patients aged 2-17 years, the pharmacokinetic parameters (assessed through a population pharmacokinetics model) were comparable to those observed in adults, indicating no need for age-based dose adjustment. For contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system (CNS) and body indications, gadopiclenol at 0.05 mmol/kg was shown to be noninferior to gadobutrol at 0.1 mmol/kg in terms of 3 lesion visualization parameters (ie, lesion border delineation, internal morphology, and contrast enhancement). Moreover, for contrast-enhanced MRI of the CNS, compared with gadobenate dimeglumine at 0.1 mmol/kg, gadopiclenol exhibited superior contrast-to-noise ratio at 0.1 mmol/kg and comparable contrast-to-noise ratio at 0.05 mmol/kg. A pooled safety analysis of 1047 participants showed a favorable safety profile for gadopiclenol. Comparative studies showed that the incidence and nature of adverse drug reactions with gadopiclenol were comparable to those observed with other GBCAs. Importantly, no significant safety concerns were identified in pediatric and elderly patients, as well as in patients with renal impairment. Overall, these findings support the clinical utility and safety of gadopiclenol for MRI in adult and pediatric patients aged 2 years and older in CNS and body indications.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Hao J, Pitrou C, Bourrinet P, et al. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol. 2023. PMID: 37812485. doi:10.1097/RLI.0000000000001025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。